Ftse Mib
32.301,04
-1,69%
DAX
17.785,40
-1,67%
S&P 500
5.446,68
-1,37%
NASDAQ
17.194,15
-2,30%
Bitcoin
64.758,64
-0,91%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Evolus Inc (EOLS) Evolus Inc (EOLS) Notizie

EOLS

Evolus (EOLS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EOLS
DataOraFonteTitoloSimboloCompagnia
31/07/202423:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EOLSEvolus Inc
31/07/202422:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EOLSEvolus Inc
31/07/202422:05Business WireEvolus Reports Second Quarter 2024 Results and Raises Full Year Revenue GuidanceNASDAQ:EOLSEvolus Inc
31/07/202414:00Business WireEvolus to Hold Investor Day on September 12, 2024NASDAQ:EOLSEvolus Inc
30/07/202414:00Business WireEvolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in AustraliaNASDAQ:EOLSEvolus Inc
25/07/202414:00Business WireEvolus to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:EOLSEvolus Inc
17/07/202414:00Business WireEvolus to Report Second Quarter Financial Results on July 31, 2024NASDAQ:EOLSEvolus Inc
01/07/202414:00Business WireEvolus Announces Appointment of Albert G. White III to Board of DirectorsNASDAQ:EOLSEvolus Inc
24/06/202414:00Business WireEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler ProductsNASDAQ:EOLSEvolus Inc
12/06/202414:00Business WireEvolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in SpainNASDAQ:EOLSEvolus Inc
07/06/202423:00Business WireEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EOLSEvolus Inc
07/06/202401:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EOLSEvolus Inc
06/06/202423:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EOLSEvolus Inc
20/05/202414:30Business WireEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE MeetingNASDAQ:EOLSEvolus Inc
15/05/202414:30Business WireEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO SummitNASDAQ:EOLSEvolus Inc
10/05/202415:10Business WireEvolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the YearNASDAQ:EOLSEvolus Inc
07/05/202422:05Business WireEvolus Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ:EOLSEvolus Inc
23/04/202422:30Business WireEvolus to Report First Quarter Financial Results on May 7, 2024NASDAQ:EOLSEvolus Inc
17/04/202422:05Business WireEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®NASDAQ:EOLSEvolus Inc
26/03/202413:00Business WireEvolus to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:EOLSEvolus Inc
11/03/202414:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EOLSEvolus Inc
11/03/202412:00Business WireEvolus Announces Pricing of $50.0 Million Underwritten Offering of Common StockNASDAQ:EOLSEvolus Inc
07/03/202422:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EOLSEvolus Inc
07/03/202422:42Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EOLSEvolus Inc
07/03/202422:05Business WireEvolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 GuidanceNASDAQ:EOLSEvolus Inc
01/03/202414:30Business WireEvolus Announces Results from European Head-to-Head Filler TrialNASDAQ:EOLSEvolus Inc
27/02/202414:30Business WireEvolus to Participate in Upcoming Leerink Partners and Barclays Investor ConferencesNASDAQ:EOLSEvolus Inc
22/02/202422:30Business WireEvolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024NASDAQ:EOLSEvolus Inc
16/01/202423:28Business WireEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 GuidanceNASDAQ:EOLSEvolus Inc
11/01/202412:18IH Market NewsWall Street Highlights: Mastercard’s Financial Rise, Citigroup’s $3.8 Billion Charges, and MoreNASDAQ:EOLSEvolus Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EOLS

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
STMMI
ST Microelectronics
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
PRY
Prysmian
BIT
IVG
Iveco Group NV
BIT
G
Generali
BIT
AZM
Azimut Hldg
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network